<DOC>
	<DOCNO>NCT02193191</DOCNO>
	<brief_summary>The purpose research study test safety efficacy drug call Plerixafor . Plerixafor approve US FDA use increase blood stem cell count collection cancer patient . It yet approve patient sickle cell disease . The investigator want find Plerixafor use increase cell count patient sickle cell disease .</brief_summary>
	<brief_title>Escalation Plerixafor Mobilization CD34+ Hematopoietic Progenitor Cells Evaluation Globin Gene Transfer Patients With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Patients must confirm measurable Sickle Cell Disease , define SS Sβ thalassemia confirm hemoglobin fractionation . ≥ 18 65 year age Patient must ECOG performance status ≤2 Karnofsky score &gt; 70 % Patients must acceptable organ marrow function define : WBC ≥ 3,000/μL ANC ≥ 1,500/μL platelet ≥150,000//μL Hemoglobin ≥ 6 gm/dL Calculated creatinine clearance ≥ 60ml/min * *Using Cockcroftgault equation [ 140 Age ( yr ) ] [ Weight ( kg ) ] x 0.85 Female 72 [ Serum Creatinine ( mg/dL ] Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Each patient must willing participate research subject must sign informed consent form . Patients : Receiving receive treatment investigational agent within 4 week prior enter study OR recover adverse event due agent administer 4 week earlier determined treat physician . Patients ALT ( SGPT ) &gt; 2.5 X upper limit normal Patients creatinine clearance &lt; 60 ml/min Patients uncontrolled illness include , limited : Ongoing active infection Emergency room admission hospitalization past 14 day Major surgery past 30 day Medical/psychiatric illness/social situation would limit compliance study requirement determine treat physician . Female patient pregnant breastfeed Patients active hepatitis B , hepatitis C , HIV infection Patients poor cardiac function define ejection fraction &lt; 40 % exclude due potential poor tolerance fluid shift leukapheresis ( patient enrol second phase protocol Leukapheresis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Plerixafor</keyword>
	<keyword>13-229</keyword>
</DOC>